Government ❯ Regulatory Agencies ❯ FDA

Drug Approval

Mifepristone Mifepristone Regulations Psychedelic Drugs Telehealth Regulations Clinical Trials MDMA Regulations Safety Monitoring Supply Chain Management Opioid Test FDA Regulations Medicine Regulation Legal Challenges Safety Evaluation Public Health Leucovorin Approval Prescription Drugs Online Prescribing Services Risk Management Safety Regulations Mifepristone Regulation Vaccines Advertising Regulations Sunscreen Ingredients Emergency Use Authorization Peptides

U.S. Lawsuits and European Finding Focus Scrutiny on GLP‑1 Drugs and Rare Vision Loss

Regulatory disagreement raises questions about labeling, patient warnings, research priorities.

Stories older than 24h

Securities Class Action Filed Against ImmunityBio After FDA Flags Anktiva Marketing

Hawley Seeks Congressional Oversight of Mifepristone After FDA Offers No Timeline on Safety Review

Republicans Push to Restore In‑Person Rules for Abortion Pill at Fiery Senate Hearing

FDA Halts Sales of Unapproved Ingestible Fluoride for Children 3 and Under

Cytokinetics Hit With Securities Class Action Over Aficamten Timeline Disclosures